Literature DB >> 20960105

Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study.

Elif Küpeli1, Gaye Ulubay, Sevinc Sarinc Ulasli, Tugce Sahin, Zeynep Erayman, Alptekin Gürsoy.   

Abstract

Studies have confirmed correlation between metabolic syndrome (MetS) and chronic obstructive pulmonary disease (COPD). However, to date, no studies have analyzed correlation between exacerbations of COPD (ECOPD) and MetS. The aim of this preliminary study was to examine if presence of MetS increases the frequency and duration of ECOPD. Patients with COPD were prospectively enrolled and followed between March 2008 and September 2009. Medical records, pulmonary function tests, chest X-rays; laboratory test results were gathered to establish the presence of COPD and MetS. Patients were divided in two groups; with and without MetS. The ECOPD was defined as worsening of symptoms requiring increased use of rescue medications and/or need for either systemic steroids or antibiotics or that led to emergency room visit or hospitalizations during 12 months follow-up. A total of 106 patients were recruited, 29 with MetS and 77 without. The mean exacerbation of COPD frequency was 2.4 ± 0.8 in MetS group versus 0.68 ± 0.6 in the control group during the follow-up period (P < 0.001). Mean duration of each exacerbation was 7.5 ± 1.5 days in patients with MetS versus 5 ± 2.4 days in patients without. Serum C-reactive protein (r = 0.31, P = 0.001), fasting blood glucose (r = 0.55, P < 0.001), and triglycerides (r = 0.251, P = 0.01) were positively and significantly correlated with exacerbation frequency. This study demonstrates an association between ECOPD and its duration with the MetS. The systemic inflammation induced by common cytokines may explain the linkage between the two conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20960105     DOI: 10.1007/s12020-010-9351-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  53 in total

Review 1.  The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies.

Authors:  Magali Poulain; Mariève Doucet; Geneviève C Major; Vicky Drapeau; Frédéric Sériès; Louis-Philippe Boulet; Angelo Tremblay; François Maltais
Journal:  CMAJ       Date:  2006-04-25       Impact factor: 8.262

Review 2.  Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis.

Authors:  Birgit Gustafson; Ann Hammarstedt; Christian X Andersson; Ulf Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-09-06       Impact factor: 8.311

3.  Biomarkers of systemic inflammation in stable and exacerbation phases of COPD.

Authors:  Fisun Karadag; Aslihan B Karul; Orhan Cildag; Mustafa Yilmaz; Hatice Ozcan
Journal:  Lung       Date:  2008-09-20       Impact factor: 2.584

Review 4.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

5.  Characteristics of physical activities in daily life in chronic obstructive pulmonary disease.

Authors:  Fabio Pitta; Thierry Troosters; Martijn A Spruit; Vanessa S Probst; Marc Decramer; Rik Gosselink
Journal:  Am J Respir Crit Care Med       Date:  2005-01-21       Impact factor: 21.405

Review 6.  Systemic effects of chronic obstructive pulmonary disease.

Authors:  A G N Agustí; A Noguera; J Sauleda; E Sala; J Pons; X Busquets
Journal:  Eur Respir J       Date:  2003-02       Impact factor: 16.671

Review 7.  Systemic manifestations and comorbidities of COPD.

Authors:  P J Barnes; B R Celli
Journal:  Eur Respir J       Date:  2009-05       Impact factor: 16.671

8.  C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men.

Authors:  D E Laaksonen; L Niskanen; K Nyyssönen; K Punnonen; T-P Tuomainen; V-P Valkonen; R Salonen; J T Salonen
Journal:  Diabetologia       Date:  2004-07-28       Impact factor: 10.122

9.  Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men.

Authors:  Tobias Pischon; Frank B Hu; Kathryn M Rexrode; Cynthia J Girman; Joann E Manson; Eric B Rimm
Journal:  Atherosclerosis       Date:  2007-08-02       Impact factor: 5.162

10.  Role of TNF-α, sTNF-R55 and sTNF-R75 in inflammation of acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Mian Zeng; Ying Wen; Ling-yun Liu; Hui Wang; Kai-pan Guan; Xiaomei Huang
Journal:  Respiration       Date:  2009-03-31       Impact factor: 3.580

View more
  17 in total

Review 1.  Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.

Authors:  Alvar Agustí; Peter M Calverley; Marc Decramer; Robert A Stockley; Jadwiga A Wedzicha
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

Review 2.  COPD and the metabolic syndrome: an intriguing association.

Authors:  Enrico Clini; Ernesto Crisafulli; Alessandro Radaeli; Mario Malerba
Journal:  Intern Emerg Med       Date:  2011-10-02       Impact factor: 3.397

3.  The association of low bone mineral density with systemic inflammation in clinically stable COPD.

Authors:  Binmiao Liang; Yulin Feng
Journal:  Endocrine       Date:  2011-12-24       Impact factor: 3.633

Review 4.  Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.

Authors:  Stanley M H Chan; Stavros Selemidis; Steven Bozinovski; Ross Vlahos
Journal:  Pharmacol Ther       Date:  2019-02-26       Impact factor: 12.310

Review 5.  Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management.

Authors:  Nirupama Putcha; M Bradley Drummond; Robert A Wise; Nadia N Hansel
Journal:  Semin Respir Crit Care Med       Date:  2015-08-03       Impact factor: 3.119

6.  COPD patients with and without metabolic syndrome: clinical and functional differences.

Authors:  Jesús Díez-Manglano; José Barquero-Romero; Pedro Almagro; Francisco Javier Cabrera; Francisco López García; Lorena Montero; Joan Baptiste Soriano
Journal:  Intern Emerg Med       Date:  2013-05-05       Impact factor: 3.397

7.  The existence of bronchiectasis predicts worse prognosis in patients with COPD.

Authors:  Bei Mao; Hai-Wen Lu; Man-Hui Li; Li-Chao Fan; Jia-Wei Yang; Xia-Yi Miao; Jin-Fu Xu
Journal:  Sci Rep       Date:  2015-06-16       Impact factor: 4.379

8.  Metabolic syndrome in hospitalized patients with chronic obstructive pulmonary disease.

Authors:  Evgeni Mekov; Yanina Slavova; Adelina Tsakova; Marianka Genova; Dimitar Kostadinov; Delcho Minchev; Dora Marinova
Journal:  PeerJ       Date:  2015-07-02       Impact factor: 2.984

Review 9.  Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony.

Authors:  Aibek E Mirrakhimov
Journal:  Cardiovasc Diabetol       Date:  2012-10-27       Impact factor: 9.951

10.  Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose.

Authors:  James P Garnett; Emma H Baker; Sonam Naik; Jodi A Lindsay; Gwenan M Knight; Simren Gill; John S Tregoning; Deborah L Baines
Journal:  Thorax       Date:  2013-05-24       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.